A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer's disease model

Alzheimer's Research and Therapy

Volumn 6, Issue 3, 2014, Pages

  Wang, Shuang ^a,b   Yu, Yang ^b,e   Geng, Shuang ^a   Wang, Dongmei ^c   Zhang, Li ^c   Xie, Xiaoping ^b   Wu, Bing ^b   Li, Chaofan ^a   Xu, Hanqian ^b   Li, Xiaolin ^d   Hu, Yanxin ^b   Zhang, Lianfeng ^c   Kaether, Christoph ^d   Wang, Bin ^a  

^a FUDAN UNIVERSITY   (China)

^b CHINA AGRICULTURAL UNIVERSITY   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d FRITZ LIPMANN INSTITUTE   (Germany)

^e INSTITUTE OF PATHOGEN BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-42]; IMMUNOGLOBULIN G;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BEHAVIOR CHANGE; CELL INFILTRATION; COGNITIVE DEFECT; CONTROLLED STUDY; ENCEPHALITIS; FEMALE; MALE; MENINGOENCEPHALITIS; MOUSE; NONHUMAN; PHASE 2 CLINICAL TRIAL; PLASMID; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 84903548059     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt256     Document Type: Article

References (65)

1. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS, Goldstein LS, Science 2005 307 1282 1288 10.1126/science.1105681 15731448
2. Anti-Aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Golde TE, Schneider LS, Koo EH, Neuron 2011 69 203 213 10.1016/j.neuron.2011.01.002 21262461
3. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Hardy J, Selkoe DJ, Science 2002 297 353 356 A published erratum appears in Science 2002, 297:2209 10.1126/science.1072994 12130773
4. Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Klunk WE, Neurobiol Aging 2011 32 20 S36 22078170
5. 1-42. Bate C, Kempster S, Last V, Williams A, J Neuroinflammation 2006 3 7 10.1186/1742-2094-3-7 16569229
6. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ, for the Alzheimer's Disease Cooperative Study, JAMA 2000 283 1007 1015 A published erratum appears in JAMA 2000, 283:2597 10.1001/jama.283.8.1007 10697060
7. Targeting β-amyloid pathology in Alzheimer's disease with Aβ immunotherapy. Nitsch R, Hock C, Neurotherapeutics 2008 5 415 420 10.1016/j.nurt.2008.05.013 18625453
8. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P, Nature 1999 400 173 177 10.1038/22124 10408445
9. Evidence for impaired amyloid β clearance in Alzheimer's disease. Wildsmith KR, Holley M, Savage JC, Skerrett R, Landreth GE, Alzheimers Res Ther 2013 5 33 10.1186/alzrt187 23849219
10. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM, for the AN1792(QS-21)-201 Study Team, Neurology 2005 64 1553 1562 10.1212/01.WNL. 0000159740.16984.3C 15883316
11. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S, Neurology 2005 64 94 101 10.1212/01.WNL.0000148604.77591.67 15642910
12. Conformation-sensitive antibodies against Alzheimer amyloid-β by immunization with a thioredoxin-constrained B-cell epitope peptide. Moretto N, Bolchi A, Rivetti C, Imbimbo BP, Villetti G, Pietrini V, Polonelli L, Del Signore S, Smith KM, Ferrante RJ, Ottonello S, J Biol Chem 2007 282 11436 11445 10.1074/jbc.M609690200 17267402
13. 28 conjugate prevents Aβ-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. Petrushina I, Ghochikyan A, Mkrtichyan M, Mamikonyan G, Movsesyan N, Ajdari R, Vasilevko V, Karapetyan A, Lees A, Agadjanyan MG, Cribbs DH, J Neuroinflammation 2008 5 42 10.1186/1742-2094-5-42 18823564
14. 1-15 in PLGA microparticles enhances serum antibody response in mice immunized by subcutaneous and intranasal routes. Puras G, Salvador A, Igartua M, Hernández RM, Pedraz JL, Eur J Pharm Sci 2011 44 200 206 10.1016/j.ejps.2011.07.010 21820509
15. Site-specific UBITh amyloid-β vaccine for immunotherapy of Alzheimer's disease. Wang CY, Finstad CL, Walfield AM, Sia C, Sokoll KK, Chang TY, Fang XD, Hung CH, Hutter-Paier B, Windisch M, Vaccine 2007 25 3041 3052 10.1016/j.vaccine.2007.01.031 17287052
16. The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. Wiessner C, Wiederhold KH, Tissot AC, Frey P, Danner S, Jacobson LH, Jennings GT, Lüönd R, Ortmann R, Reichwald J, Zurini M, Mir A, Bachmann MF, Staufenbiel M, J Neurosci 2011 31 9323 9331 10.1523/JNEUROSCI.0293-11.2011 21697382
17. Development of AFFITOPE vaccines for Alzheimer's disease (AD)-from concept to clinical testing. Schneeberger A, Mandler M, Otawa O, Zauner W, Mattner F, Schmidt W, J Nutr Health Aging 2009 13 264 267 10.1007/s12603-009- 0070-5 19262965
18. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A, The Lancet Neurology 2012 11 597 604 10.1016/S1474-4422(12)70140-0
19. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T, Nat Med 2000 6 916 919 10.1038/78682 10932230
20. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T, Proc Natl Acad Sci U S A 2003 100 2023 2028 A published erratum appears in Proc Natl Acad Sci U S A 2004, 101: 11526 10.1073/pnas.0436286100 12566568
21. Short amyloid-β (Aβ) immunogens reduce cerebral Aβ load and learning deficits in an Alzheimer's disease mouse model in the absence of an Aβ-specific cellular immune response. Maier M, Seabrook TJ, Lazo ND, Jiang L, Das P, Janus C, Lemere CA, J Neurosci 2006 26 4717 4728 10.1523/JNEUROSCI. 0381-06.2006 16672644
22. Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. Wilcock DM, Colton CA, CNS Neurol Disord Drug Targets 2009 8 50 64 10.2174/187152709787601858 19275636
23. Intracranially administered anti-Aβ antibodies reduce β-amyloid deposition by mechanisms both independent of and associated with microglial activation. Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D, J Neurosci 2003 23 3745 3751 12736345
24. Amyloid-β vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN, Neuroscience 2007 144 950 960 10.1016/j.neuroscience.2006.10.020 17137722
25. Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrence. Wilcock DM, Morgan D, Gordon MN, Taylor TL, Ridnour LA, Wink DA, Colton CA, J Neuroinflammation 2011 8 115 10.1186/1742-2094-8-115 21906275
26. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM, Nat Neurosci 2002 5 452 457 11941374
27. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM, Proc Natl Acad Sci U S A 2001 98 8850 8855 10.1073/pnas.151261398 11438712
28. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, Nichols A, Grundman M, Alzheimer Dis Assoc Disord 2010 24 198 203 10.1097/WAD. 0b013e3181c53b00 20505438
29. MER5101, a novel Aβ1-15:DT conjugate vaccine, generates a robust anti-Aβ antibody response and attenuates Aβ pathology and cognitive deficits in APPswe/PSΔ1E9 transgenic mice. Liu B, Frost JL, Sun J, Fu H, Grimes S, Blackburn P, Lemere CA, J Neurosci 2013 33 7027 7037 10.1523/JNEUROSCI.5924-12.2013 23595760
30. A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease. Lambracht-Washington D, Qu B, Fu M, Anderson LD Jr, Eagar TN, Stüve O, Rosenberg RN, J Neuroimmunol 2013 254 63 68 10.1016/j.jneuroim.2012.09.008 23036592
31. + regulatory T cells in self-tolerance and autoimmune disease. Sakaguchi S, Setoguchi R, Yagi H, Nomura T, Curr Top Microbiol Immunol 2006 305 51 66 16724800
32. Induction of Adaptive T Regulatory Cells That Suppress the Allergic Response by Coimmunization of DNA and Protein Vaccines. Jin H, Kang Y, Zhao L, Xiao C, Hu Y, She R, Yu Y, Du X, Zhao G, Ng T, Chu HJ, Wang B, J Immunol 2008 180 5360 5372 10.4049/jimmunol.180.8.5360 18390718
33. Induction of active immune suppression by co-immunization with DNA- and protein-based vaccines. Jin H, Kang Y, Zheng G, Xie Q, Xiao C, Zhang X, Yu Y, Zhu K, Zhao G, Zhang F, Chen A, Wang B, Virology 2005 337 183 191 10.1016/j.virol.2005.03.029 15914231
34. Caveolin-1-Mediated Negative Signaling Plays a Critical Role in the Induction of Regulatory Dendritic Cells by DNA and Protein Coimmunization. Li J, Geng S, Xie X, Liu H, Zheng G, Sun X, Zhao G, Wan Y, Wu Y, Chen X, Zhong Y, Wang B, J Immunol 2012 189 2852 2859 10.4049/jimmunol.1102828 22904311
35. Construction and identification of eukaryotic expression vector of homo sapiens amyloid precursor protein (APP). Chang Y, Zhu H, Cai YY, Chin J Gerontol 1999 16 42 44
36. Establishment of the transgenic model of Alzheimer's disease. Chang Y, Qin C, Yin H, Zhu H, Cai Y, Acta Anat Sin 2000 31 144 147
37. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. Feng Z, Chang Y, Cheng Y, Zhang B, Qu Z, Qin C, Zhang J, J Pineal Res 2004 37 129 136 10.1111/j.1600-079X.2004.00144.x 15298672
38. Aβ42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jäggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, Hölscher C, Mathews PM, Jucker M, EMBO Rep 2006 7 940 946 10.1038/sj.embor.7400784 16906128
39. IMPY: an improved thioflavin-T derivative for in vivo labeling of β-amyloid plaques. Kung MP, Hou C, Zhuang ZP, Zhang B, Skovronsky D, Trojanowski JQ, Lee VMY, Kung HF, Brain Res 2002 956 202 210 10.1016/S0006-8993(02)03436-4 12445687
40. Morphological characterization of thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Aβ immunotherapy on their clearance. Bussière T, Bard F, Barbour R, Grajeda H, Guido T, Khan K, Schenk D, Games D, Seubert P, Buttini M, Am J Pathol 2004 165 987 995 10.1016/S0002-9440(10)63360-3 15331422
41. Long-term changes in open field behaviour following a single social defeat in rats can be reversed by sleep deprivation. Meerlo P, Overkamp GJ, Benning MA, Koolhaas JM, Van den Hoofdakker RH, Physiol Behav 1996 60 115 119 10.1016/0031-9384(95)02271-6 8804650
42. Involvement of hippocampal NMDA and AMPA receptors in acquisition, formation and retrieval of spatial memory in the Morris water maze. Liang KC, Hon W, Tyan YM, Liao WL, Chin J Physiol 1994 37 201 212 7796636
43. Long-term naringin consumption reverses a glucose uptake defect and improves cognitive deficits in a mouse model of Alzheimer's disease. Wang D, Gao K, Li X, Shen X, Zhang X, Ma C, Qin C, Zhang L, Pharmacol Biochem Behav 2012 102 13 20 10.1016/j.pbb.2012.03.013 22741174
44. Treg Cell Resistance to Apoptosis in DNA Vaccination for Experimental Autoimmune Encephalomyelitis Treatment. Kang Y, Sun Y, Zhang J, Gao W, Kang J, Wang Y, Wang B, Xia G, PLoS One 2012 7 49994 10.1371/journal.pone.0049994 23166807
45. Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. Cissé M, Sanchez PE, Kim DH, Ho K, Yu GQ, Mucke L, J Neurosci 2011 31 10427 10431 A published erratum appears in J Neurosci 2011, 31: 14046 10.1523/JNEUROSCI.1459-11.2011 21775587
46. Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Kobayashi DT, Chen KS, Genes Brain Behav 2005 4 173 196 10.1111/j.1601-183X.2005.00124.x 15810905
47. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Aβ oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. Meilandt WJ, Cissé M, Ho K, Wu T, Esposito LA, Scearce-Levie K, Cheng IH, Yu GQ, Mucke L, J Neurosci 2009 29 1977 1986 10.1523/JNEUROSCI.2984-08.2009 19228952
48. Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Furlan R, Brambilla E, Sanvito F, Roccatagliata L, Olivieri S, Bergami A, Pluchino S, Uccelli A, Comi G, Martino G, Brain 2003 126 285 291 10.1093/brain/awg031 12538398
49. DNA and protein co-administration induces tolerogenic dendritic cells through DC-SIGN mediated negative signals. Li J, Geng S, Liu X, Liu H, Jin H, Liu CG, Wang B, Hum Vaccin Immunother 2013 9 2237 2245 24051433
50. A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice. Zheng L, Wang F, Yang Z, Chen J, Chang H, Chen Z, BMC Infect Dis 2009 9 17 10.1186/1471-2334-9-17 19216752
51. Interleukin-1 mediates Alzheimer and Lewy body pathologies. Griffin WS, Liu L, Li Y, Mrak RE, Barger SW, J Neuroinflammation 2006 3 5 10.1186/1742-2094-3-5 16542445
52. Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor. Veerhuis R, Janssen I, De Groot CJ, Van Muiswinkel FL, Hack CE, Eikelenboom P, Exp Neurol 1999 160 289 299 10.1006/exnr.1999.7199 10630213
53. QS-21: a water-soluble triterpene glycoside adjuvant. Kensil CR, Kammer R, Expert Opin Investig Drugs 1998 7 1475 1482 10.1517/13543784.7.9.1475 15992044
54. Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Ragupathi G, Gardner JR, Livingston PO, Gin DY, Expert Rev Vaccines 2011 10 463 470 10.1586/erv.11.18 21506644
55. Adjuvant activity of cytokines. Tovey MG, Lallemand C, Methods Mol Biol 2010 626 287 309 10.1007/978-1-60761-585-9-19 20099135
56. Experimental autoimmune encephalomyelitis as a testing paradigm for adjuvants and vaccines. Libbey JE, Fujinami RS, Vaccine 2011 29 3356 3362 10.1016/j.vaccine.2010.08.103 20850537
57. TLR-dependent T cell activation in autoimmunity. Mills KH, Nat Rev Immunol 2011 11 807 822 22094985
58. Progress in understanding adjuvant immunotoxicity mechanisms. Batista-Duharte A, Lindblad EB, Oviedo-Orta E, Toxicol Lett 2011 203 97 105 10.1016/j.toxlet.2011.03.001 21392560
59. Eisai Co Ltd, Eisai Announces The Start of the First Clinical Study of BAN2401, a Novel Monoclonal Anti-body Targeting the Neurotoxic Protofibrils Believed to Cause Alzheimer's Disease Tokyo: Eisai Co, Ltd [News Release, Vol. 9]. 2010 11 40
60. Safety and pharmacokinetics following a single 10-minute intravenous infusion of the anti-amyloid mAb ponezumab (PF-04360365) in patients with mild to moderate Alzheimer's disease [Abstract]. Burstein AH, Zhao Q, Ross J, Styren S, Landen JW, Ma WM, McCush F, Alvey C, Kupiec JT, Bednar MM, Alzheimers Dement 2010 6 585
61. Solanezumab was safe and well-tolerated for Asian patients with mild-to-moderate Alzheimer's disease in a multicenter, randomized, open-label, multi-dose study [Abstract]. Goto T, Fujikoshi S, Uenaka K, Nishiuma S, Siemers ER, Dean RA, Takahashi M, Alzheimers Dement 2010 6 308
62. Antigen-specific TGF-β1 secretion with bovine myelin oral tolerization in multiple sclerosis. Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA, Ann N Y Acad Sci 1996 778 251 257 10.1111/j.1749-6632. 1996.tb21133.x 8610978
63. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG, Nature 1997 389 737 742 10.1038/39614 9338786
64. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Roncarolo MG, Battaglia M, Nat Rev Immunol 2007 7 585 598 10.1038/nri2138 17653126
65. + regulatory T cells in human autoimmune diseases. Buckner JH, Nat Rev Immunol 2010 10 849 859 10.1038/nri2889 21107346